JP2011510029A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011510029A5 JP2011510029A5 JP2010543387A JP2010543387A JP2011510029A5 JP 2011510029 A5 JP2011510029 A5 JP 2011510029A5 JP 2010543387 A JP2010543387 A JP 2010543387A JP 2010543387 A JP2010543387 A JP 2010543387A JP 2011510029 A5 JP2011510029 A5 JP 2011510029A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- isoindol
- dihydro
- oxo
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 37
- 150000003839 salts Chemical class 0.000 claims 28
- 239000000203 mixture Substances 0.000 claims 26
- -1 5-chloro-pyridin-2-yl Chemical group 0.000 claims 13
- 125000004432 carbon atom Chemical group C* 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 12
- 239000002671 adjuvant Substances 0.000 claims 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000002619 bicyclic group Chemical group 0.000 claims 8
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 8
- 125000002950 monocyclic group Chemical group 0.000 claims 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 8
- 125000004430 oxygen atom Chemical group O* 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000004434 sulfur atom Chemical group 0.000 claims 8
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 4
- 150000001408 amides Chemical class 0.000 claims 4
- 235000010290 biphenyl Nutrition 0.000 claims 4
- 239000004305 biphenyl Substances 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- APRATTNDLORJFG-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)-n-pyridin-2-ylpropanamide Chemical compound C1=C(OC)C(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=CC=N1 APRATTNDLORJFG-UHFFFAOYSA-N 0.000 claims 2
- RMUULXHVYNHZBF-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-n-(5-methylpyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=C(C)C=N1 RMUULXHVYNHZBF-UHFFFAOYSA-N 0.000 claims 2
- OEJXYAKMUUFPMI-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-n-(6-methylpyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=CC(C)=N1 OEJXYAKMUUFPMI-UHFFFAOYSA-N 0.000 claims 2
- SBVFNYIOAWKDSB-UHFFFAOYSA-N 3-(3-oxo-1h-isoindol-2-yl)-n-(1,3-thiazol-2-yl)-3-(3,4,5-trimethoxyphenyl)propanamide Chemical compound COC1=C(OC)C(OC)=CC(C(CC(=O)NC=2SC=CN=2)N2C(C3=CC=CC=C3C2)=O)=C1 SBVFNYIOAWKDSB-UHFFFAOYSA-N 0.000 claims 2
- DZIWVUSUJHPTIN-UHFFFAOYSA-N 3-(3-oxo-1h-isoindol-2-yl)-n-pyridin-2-yl-3-(3,4,5-trimethoxyphenyl)propanamide Chemical compound COC1=C(OC)C(OC)=CC(C(CC(=O)NC=2N=CC=CC=2)N2C(C3=CC=CC=C3C2)=O)=C1 DZIWVUSUJHPTIN-UHFFFAOYSA-N 0.000 claims 2
- IPSFXCHUNUDSKS-UHFFFAOYSA-N 3-(3-oxo-1h-isoindol-2-yl)-n-pyridin-2-yl-3-thiophen-2-ylpropanamide Chemical compound C=1C=CC=NC=1NC(=O)CC(N1C(C2=CC=CC=C2C1)=O)C1=CC=CS1 IPSFXCHUNUDSKS-UHFFFAOYSA-N 0.000 claims 2
- XRUMTIMHZVQDQA-UHFFFAOYSA-N 3-(4-methoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)-n-pyridin-2-ylpropanamide Chemical compound C1=CC(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=CC=N1 XRUMTIMHZVQDQA-UHFFFAOYSA-N 0.000 claims 2
- ITRSBXAOJQVEOW-UHFFFAOYSA-N 3-(4-methoxyphenyl)-n-(4-methylpyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=CC(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC(C)=CC=N1 ITRSBXAOJQVEOW-UHFFFAOYSA-N 0.000 claims 2
- QXIJITNYCCMZDI-UHFFFAOYSA-N 3-(4-methoxyphenyl)-n-(5-methylpyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=CC(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=C(C)C=N1 QXIJITNYCCMZDI-UHFFFAOYSA-N 0.000 claims 2
- PMYSKYMHOVWMAB-UHFFFAOYSA-N 3-(4-methoxyphenyl)-n-(6-methylpyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=CC(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=CC(C)=N1 PMYSKYMHOVWMAB-UHFFFAOYSA-N 0.000 claims 2
- 102000030595 Glucokinase Human genes 0.000 claims 2
- 108010021582 Glucokinase Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- IBRUVOZFXCYUPN-UHFFFAOYSA-N n-(5-bromopyridin-2-yl)-3-(3,4-dimethoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=C(Br)C=N1 IBRUVOZFXCYUPN-UHFFFAOYSA-N 0.000 claims 2
- BPWWAPBGDABIHH-UHFFFAOYSA-N n-(5-bromopyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)-3-(3,4,5-trimethoxyphenyl)propanamide Chemical compound COC1=C(OC)C(OC)=CC(C(CC(=O)NC=2N=CC(Br)=CC=2)N2C(C3=CC=CC=C3C2)=O)=C1 BPWWAPBGDABIHH-UHFFFAOYSA-N 0.000 claims 2
- KTMPTXPTUBHTDC-UHFFFAOYSA-N n-(5-bromopyridin-2-yl)-3-(4-methylphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=CC(C)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=C(Br)C=N1 KTMPTXPTUBHTDC-UHFFFAOYSA-N 0.000 claims 2
- KMDDPCCZBHXPDA-UHFFFAOYSA-N n-(5-chloropyridin-2-yl)-3-(3,4-dimethoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=C(Cl)C=N1 KMDDPCCZBHXPDA-UHFFFAOYSA-N 0.000 claims 2
- HQANKEHGKYKJBR-UHFFFAOYSA-N n-(5-chloropyridin-2-yl)-3-(4-fluorophenyl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=CC(F)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=C(Cl)C=N1 HQANKEHGKYKJBR-UHFFFAOYSA-N 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- STOZBSVDJISXRI-UHFFFAOYSA-N n-(4-methyl-1,3-thiazol-2-yl)-3-(3-oxo-1h-isoindol-2-yl)-3-(3,4,5-trimethoxyphenyl)propanamide Chemical compound COC1=C(OC)C(OC)=CC(C(CC(=O)NC=2SC=C(C)N=2)N2C(C3=CC=CC=C3C2)=O)=C1 STOZBSVDJISXRI-UHFFFAOYSA-N 0.000 claims 1
- CYEJTXYXGQXFTD-UHFFFAOYSA-N n-(5-methylpyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)-3-(3,4,5-trimethoxyphenyl)propanamide Chemical compound COC1=C(OC)C(OC)=CC(C(CC(=O)NC=2N=CC(C)=CC=2)N2C(C3=CC=CC=C3C2)=O)=C1 CYEJTXYXGQXFTD-UHFFFAOYSA-N 0.000 claims 1
- BXKIVTINPIYLNI-UHFFFAOYSA-N n-(6-methylpyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)-3-(3,4,5-trimethoxyphenyl)propanamide Chemical compound COC1=C(OC)C(OC)=CC(C(CC(=O)NC=2N=C(C)C=CC=2)N2C(C3=CC=CC=C3C2)=O)=C1 BXKIVTINPIYLNI-UHFFFAOYSA-N 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08001305.5 | 2008-01-24 | ||
| EP08001305 | 2008-01-24 | ||
| PCT/EP2008/011099 WO2009092432A1 (en) | 2008-01-24 | 2008-12-23 | Beta-amino acid derivatives for treatment of diabetes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011510029A JP2011510029A (ja) | 2011-03-31 |
| JP2011510029A5 true JP2011510029A5 (enExample) | 2012-02-16 |
| JP5623914B2 JP5623914B2 (ja) | 2014-11-12 |
Family
ID=40386192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010543387A Expired - Fee Related JP5623914B2 (ja) | 2008-01-24 | 2008-12-23 | 糖尿病を処置するためのβアミノ酸誘導体 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8431602B2 (enExample) |
| EP (1) | EP2231640B1 (enExample) |
| JP (1) | JP5623914B2 (enExample) |
| KR (1) | KR20100110367A (enExample) |
| CN (1) | CN101925596B (enExample) |
| AR (1) | AR070232A1 (enExample) |
| AU (1) | AU2008348817B2 (enExample) |
| BR (1) | BRPI0821827A2 (enExample) |
| CA (1) | CA2712998A1 (enExample) |
| CY (1) | CY1112919T1 (enExample) |
| DK (1) | DK2231640T3 (enExample) |
| EA (1) | EA017775B1 (enExample) |
| ES (1) | ES2388475T3 (enExample) |
| HR (1) | HRP20120510T1 (enExample) |
| IL (1) | IL206904A0 (enExample) |
| MX (1) | MX2010007926A (enExample) |
| PL (1) | PL2231640T3 (enExample) |
| PT (1) | PT2231640E (enExample) |
| SI (1) | SI2231640T1 (enExample) |
| WO (1) | WO2009092432A1 (enExample) |
| ZA (1) | ZA201006002B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP3365334B1 (en) | 2015-10-21 | 2024-07-17 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| WO2024229228A2 (en) * | 2023-05-02 | 2024-11-07 | The Rockefeller University | 1-oxoisoindolin-2-yl amide activators of vcp and derivatives thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| US6482951B2 (en) * | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
| MXPA05003889A (es) * | 2002-10-15 | 2005-06-22 | Celgene Corp | Farmacos inhibidores de citosina selectiva para tratar sindrome mielodisplastico. |
| ATE449081T1 (de) * | 2002-12-30 | 2009-12-15 | Celgene Corp | Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen |
| CN101309585A (zh) * | 2004-10-28 | 2008-11-19 | 细胞基因公司 | 使用pde4调节剂治疗和控制中枢神经系统损伤的方法和组合物 |
| JP5386350B2 (ja) * | 2006-05-31 | 2014-01-15 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体 |
-
2008
- 2008-12-23 CN CN200880125427.7A patent/CN101925596B/zh not_active Expired - Fee Related
- 2008-12-23 US US12/864,348 patent/US8431602B2/en not_active Expired - Fee Related
- 2008-12-23 PL PL08871581T patent/PL2231640T3/pl unknown
- 2008-12-23 EP EP08871581A patent/EP2231640B1/en not_active Not-in-force
- 2008-12-23 WO PCT/EP2008/011099 patent/WO2009092432A1/en not_active Ceased
- 2008-12-23 KR KR1020107018265A patent/KR20100110367A/ko not_active Ceased
- 2008-12-23 SI SI200830736T patent/SI2231640T1/sl unknown
- 2008-12-23 JP JP2010543387A patent/JP5623914B2/ja not_active Expired - Fee Related
- 2008-12-23 ES ES08871581T patent/ES2388475T3/es active Active
- 2008-12-23 DK DK08871581.8T patent/DK2231640T3/da active
- 2008-12-23 BR BRPI0821827-7A patent/BRPI0821827A2/pt not_active IP Right Cessation
- 2008-12-23 PT PT08871581T patent/PT2231640E/pt unknown
- 2008-12-23 EA EA201001174A patent/EA017775B1/ru not_active IP Right Cessation
- 2008-12-23 MX MX2010007926A patent/MX2010007926A/es active IP Right Grant
- 2008-12-23 CA CA2712998A patent/CA2712998A1/en not_active Abandoned
- 2008-12-23 AU AU2008348817A patent/AU2008348817B2/en not_active Ceased
- 2008-12-23 HR HRP20120510AT patent/HRP20120510T1/hr unknown
-
2009
- 2009-01-23 AR ARP090100201A patent/AR070232A1/es unknown
-
2010
- 2010-07-08 IL IL206904A patent/IL206904A0/en unknown
- 2010-08-23 ZA ZA2010/06002A patent/ZA201006002B/en unknown
-
2012
- 2012-07-24 CY CY20121100656T patent/CY1112919T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011510029A5 (enExample) | ||
| CA2774647C (en) | Substituted amide compound | |
| JP5517935B2 (ja) | 細胞壊死阻害剤としてのインドール及びインダゾール化合物 | |
| ES2367126T3 (es) | Derivados de 5-([1,3,4]oxadiazol-2-il)-1h-indazol y 5-([1,3,4]tiadiazol-2-il)-1h-indazol como inhibidores para el tratamiento de diabetes. | |
| TWI376370B (en) | Compounds for inflammation and immune-related uses | |
| TWI641595B (zh) | 氰基三唑化合物類 | |
| AU2008250706B2 (en) | Heterocyclic indazole derivatives | |
| HRP20120510T1 (hr) | Derivati beta amino kiseline za liječenje dijabetesa | |
| CA2718383A1 (en) | Heteroaryl-substituted dicyanopyridines and use thereof for treatment of cardiovascular diseases | |
| JP2017523972A5 (enExample) | ||
| MX2007008290A (es) | Compuestos para inflamacion y usos inmuno-relacionados. | |
| JP2014511869A5 (enExample) | ||
| JP2009523165A5 (enExample) | ||
| NZ590355A (en) | Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient | |
| JP2007538024A5 (enExample) | ||
| JP2008501760A5 (enExample) | ||
| RU2015101210A (ru) | Производные тиофена, используемые для лечения сахарного диабета | |
| RU2015104962A (ru) | Ди- и тригетероарильные производные в качестве ингибиторов агрегации белков | |
| JP2007532607A5 (enExample) | ||
| RU2014107000A (ru) | Производные 3-гетероароиламинопропионовой кислоты и их применение в качестве лекарственных средств | |
| JP2007505105A5 (enExample) | ||
| WO2003090869A1 (en) | Lxr modulators | |
| JP2010519278A5 (enExample) | ||
| RU2012155691A (ru) | Производные сложного аминоэфира алкалоида и их лекарственные композиции | |
| JP2011524362A5 (enExample) |